Clinical Trial

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

Study acronym: ADVANCE SC+
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Phase 3 study to evaluate the safety and efficacy of efgartigimod PH20 subcutaneous in adult patients with primary immune thrombocytopenia
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2021-03-19; most recent amendment 2026-01-09.
Status change: Recruiting → Active, Not Recruiting 2023-11-09
Status change: Not Yet Recruiting → Recruiting 2021-12-03
Trial Details
NCT Number NCT04812925
Lead Sponsor argenx
Conditions Primary Immune Thrombocytopenia
Enrollment 173 participants
Start Date 2021-11-17
Primary Completion 2026-10-01 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-12